Peregrine Pharma Target RAISED and 1 Stock Analysis to Eye

September 10, 2012

Hospira Inc. (NYSE:HSP) has been removed from U.S. Focus List at Bank of America Merrill Lynch.

Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) target has been raised by Roth Capital following the company’s report of statistically significant Phase IIb survival data for bavituximab in 2nd line NSCLC. The firm continues to be highly encouraged by the data, and it keeps a Buy rating on the stock. It continues to name Peregrine as a Focus Pick.

Don’t Miss: Who Will Be the VICTORS as Tech Giants Release NEW Products for Fall?

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com